НовостиBenzingaRoche Expands Alzheimer’s Pipeline With New Phase II TARBELA-AD Trial Of Oral NLRP3 Inhibitor RG6434, To Present Trontinemab, PrevenTRON, Elecsys Blood Test Data At CTAD November 16-19 Roche Expands Alzheimer’s Pipeline With New Phase II TARBELA-AD Trial Of Oral NLRP3 Inhibitor RG6434, To Present Trontinemab, PrevenTRON, Elecsys Blood Test Data At CTAD November 16-19 Benzinga 2026.11.10 06:25 (GMT+0) Открыть на Benzinga Другие новости